2023-04-22 06:02:36
A unique technology in the world. HCS Pharma is a Lille biotechnology company focused on the development of “in vitro” research. This process makes it possible to study the molecules of diseased human cells, such as tumors, by artificially recreating these organs in order to be able to carry out tests without risk and to find drugs adapted to the diseases.
The difficulty is to imitate the human organ as precisely as possible, using stem cells. The company also has automated microscopes, which allow it to produce color cell images. An effective way to control the slightest changes in the study of reconstructed organs.
Regenerate diseased organs
In his Lille laboratory, around twenty researchers, alongside university colleagues, study metabolic diseases (linked to the liver) and degenerative diseases (such as Parkinson’s or Alzheimer’s). In particular, they are working on several projects centered on oncology, more specifically on cancers of the liver, pancreas and lung.
In April 2022, HCS Pharma filed an application patent in Europe concerning the manufacture of mini-livers from patient cells. A year later, the patent was extended to Asia and the United States, advanced territories in medical research and innovation. The objective is to discover effective therapies against certain liver diseases.
Soon animal meat in vitro?
A researcher for ten years in the pharmaceutical industry, Nathalie Maubon decided to set up her own company in 2014, accompanied by another start-up, which already had this technology for creating human organs from stem cells. . Three years later, she became independent, convinced that the regeneration of diseased organs and their transplantation in vitro were the future of medicine.
“We are the only ones to have this unique technology since the bankruptcy of the start-up”, says Nathalie Maubon. The biologist hopes to revolutionize the pharmaceutical industry. His company has just been selected by the France Relance plan, alongside Inserm (National Institute for Health and Medical Research), CNRS (National Center for Scientific Research) and the Lille hospital center.
Another project is close to the CEO’s heart. The technology, used today for human organs, could one day be adapted to the recreation of animal cells, that is to say, animal meat created in vitro. But this project will not see the light of day for several years.
1682167074
#Human #organs #stem #cells #test #drugs #risk